Home » Stocks » X4 Pharmaceuticals

X4 Pharmaceuticals, Inc. (XFOR)

Stock Price: $5.98 USD -0.42 (-6.56%)
Updated Oct 27, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 97.39M
Revenue (ttm) 3.00M
Net Income (ttm) -54.83M
Shares Out 16.29M
EPS (ttm) -3.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 27, 2020
Last Price $5.98
Previous Close $6.40
Change ($) -0.42
Change (%) -6.56%
Day's Open 6.56
Day's Range 5.80 - 6.56
Day's Volume 94,133
52-Week Range 5.80 - 15.00

More Stats

Market Cap 97.39M
Enterprise Value 21.43M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 16.29M
Float 13.26M
EPS (basic) -2.86
EPS (diluted) -3.08
FCF / Share -2.48
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 307,618
Short Ratio 2.38
Short % of Float 2.32%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 32.46
PB Ratio 0.99
Revenue 3.00M
Operating Income -53.09M
Net Income -54.83M
Free Cash Flow -49.73M
Net Cash 75.96M
Net Cash / Share 4.66
Gross Margin 100.00%
Operating Margin -1,769.67%
Profit Margin -1,827.80%
FCF Margin -1,657.57%
ROA -21.82%
ROE -54.55%
ROIC -206.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 8
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(234.45% upside)
Current: $5.98
Target: 20.00
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-51.70-29.09-22.25-24.35-14.83
Net Income-52.81-33.29-21.99-22.98-13.22
Shares Outstanding11.530.460.460.090.08
Earnings Per Share-4.63-79.15-54.58-268.74-156.12
Operating Cash Flow-48.06-25.42-21.31-21.64-10.82
Capital Expenditures-0.17--0.38-0.07-0.17
Free Cash Flow-48.23-25.42-21.69-21.71-10.99
Cash & Equivalents1268.1377.153.437.10
Total Debt22.919.8312.2415.297.19
Net Cash / Debt103-1.7064.91-11.86-0.10
Book Value129-77.0958.71-56.56-34.32
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name X4 Pharmaceuticals, Inc.
Country United States
Employees 64
CEO Paula S. Ragan

Stock Information

Ticker Symbol XFOR
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: XFOR


X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer. Its lead drug candidate is mavorixafor (X4P-001), an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenström macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell renal cell carcinoma. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat primary immune-deficiencies. It has a license agreement with Abbisko Therapeutics Company to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was formerly known as Arsanis, Inc. and changed its name to X4 Pharmaceuticals, Inc. in March 2019. X4 Pharmaceuticals, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.